论文部分内容阅读
美国FDA已接受了葛兰素史克公司(GlaxoSmithKline)提出的、将宫颈癌作为其拓扑酶Ⅰ抑制剂托泊替康(topotecan,商品名Hycamtin,和美新)的新适应证的申请,并同意对该药进行优先考察。托泊替康是葛兰素史克公司在1998年获准上市的产品,用于初始或序贯化疗失败的转移性卵巢癌及对化
The U.S. FDA has accepted an application by GlaxoSmithKline for a new indication of cervical cancer as a topotecan that is a topoisomerase I inhibitor (Hycamtin and Miocentre) and agreed that This medicine is prioritized. Topotecan is a product approved by the GSK in 1998 for initial or sequential chemotherapy failure of metastatic ovarian cancer and chemotherapy